Antengene Corp Ltd obtained approval from University of Texas MD Anderson Cancer Center's Institutional Review Board for a Phase I trial of its prime anti-CD24 antibody, ATG-031, focusing on advanced hematology and oncology solutions.

Alvotech declared today that the U.S. FDA has agreed to Alvotech's revised BLA for AVT02.

Vir Biotechnology, Inc. reports first participant dosed in Phase 1 trial evaluating safety, reactogenicity, and immunogenicity of VIR-1388.

Hepagene Therapeutics revealed that its IND application forHPG7233 has been approved by the FDA in the United States.

Sapience Therapeutics publicizes the demonstration of ST101 Clinical findings at the International Conference on Molecular Targets and Cancer Therapeutics held by AACR-NCI-EORTC in 2023.

SpyBiotech has declared that they've submitted a clinical trial request to the U.K. MHRA for SPYVLP01 assessment.

Merck has reported that the U.S. FDA is conducting a priority analysis on a fresh sBLA petitioning for authorization of KEYTRUDA, Merck’s anti-PD-1 treatment.

The Menarini Group,together with their fully owned subsidiary Stemline Therapeutics Inc., declared that ORSERDU® (elacestrant) has received authorisation from the European Commission.

Orchard Therapeutics, a renowned leader in gene therapy worldwide, reported that the U.S. FDA has approved the submission of their BLA for OTL-200.

Rani Therapeutics Holdings proclaimed the launch of a Phase 1 clinical investigation assessing the safety and tolerability of RT-111.

LAPIX Therapeutics, Inc. announced U.S. FDA clearance of its IND application. The approval enables Phase 1 trials for its leader compound, LPX-TI641, aimed at treating multiple sclerosis.

Revolution Medicines, Inc. has initiated Phase 1/1b trials for RMC-9805, a covalent, oral KRAS G12D inhibitor for RAS-dependent cancers and the first patient already dosed targeting KRAS G12D mutation-driven cancers.